Previous 10 | Next 10 |
“Advancing Ayurveda Through Ethnobiology Drug Development” Topics Include Mateon’s ARTIShield ™ for the Treatment of COVID-19 and COVID-19/Influenza Coinfection AGOURA HILLS, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mateon T...
Dr. Kshirsagar will speak on ARTIShield™ at Delhi University on Oct 28, 2020 in his talk titled “Ayurveda concepts of Pandemic and Immunity” Dr. Kshirsagar is advisor to Mateon on its Ayurvedic product ARTIShield™ in a global clinical trial to treat COVID-1...
Mateon Therapeutics ([[MATN]] +2.7%) to commence Phase 2 clinical trial of OT-101, its lead candidate for the potential treatment of COVID-19 after recieving approval from, the regulatory agency of Argentina.The study will enroll ~24 patients in Argentina with an aggregate...
AGOURA HILLS, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Republica Argentina – Poder Ejecutivo Nacional, the regulatory agency of Argentina, ...
AGOURA HILLS, California, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that Dr. Vuong Trieu, President and CEO of Mateon, will present clinical ...
AGOURA HILLS, California, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that Dr. Vuong Trieu, President and CEO of Mateon, will present a company...
Mateon Therapeutics ([[MATN]] +1.1%) has enrolled first patient in its Phase IV study ARTI-19 study with India to contribute at least 120 patients to the total aggregate of 3000 patients. The study evaluates the safety and efficacy of Artemisia absinthium Powder 500mg...
TOP-LINE DATA ANTICIPATED IN FOURTH QUARTER 2020 AGOURA HILLS, California, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced the first patient en...
Mateon Therapeutics ([[MATN]] +3.7%) has announced that ArtiShield is now approved for manufacture and marketing by the Ministry of AYUSH, for the treatment of various symptoms like fever and inflammation. ArtiShield is in co-development with Windlas Biotech, Mateon’s commerc...
AGOURA HILLS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that ArtiShield TM is now approved for manufacture and marketing by the Ministry...
News, Short Squeeze, Breakout and More Instantly...
Mateon Therapeutics Inc. Company Name:
MATN Stock Symbol:
OTCMKTS Market:
Mateon Therapeutics Inc. Website:
AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phase 1b clinical trial of a patented OT-101/IL-2 combination. This phase 1b clinical trial w...
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon”) (OTCQB:MATN) announced today that it has completed t...
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health, and Windlas Biotech Pvt. Ltd. (Windlas), a leading I...